They also validated the capability of DESI-MS to differentiate the IDH mutation status of the tumor via detection of 2-HG and to examine the resection cavity walls for residual tumor, estimating tumor cell percentage (TCP) at surgical margins with 93% sensitivity and 83% specificity [53]. The gene discussed is IDH2; the disease is neoplasm.